Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138236 | 0.83 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL22946716 | 0.81 | — | — | |
| SCHEMBL23562270 | 0.80 | ASGR1 (0.32) | DGAT1ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL12209106 | 0.80 | ASGR1 (0.39) | CA14ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL15908023 | 0.80 | CTSD (0.34) | CA14CA12CA1ASGR1CA7 | |
| SCHEMBL18587027 | 0.79 | CA14 (0.38) | CA14CA12CA2CA1MEN1 | |
| SCHEMBL29818922 | 0.78 | ASGR1 (0.33) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL7610203 | 0.78 | ASGR1 (0.33) | CA14ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL7608850 | 0.77 | ASGR1 (0.35) | CA14ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL6138376 | 0.75 | HDAC6 (0.33) | CA14ASGR1HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | CA14 3066/4885CA12 3079/4885CA2 2248/4885 |
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | CA14 1259/4885CA12 1450/4885CA2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.